Stage III Colon Cancer: Cellular Characteristics, Symptoms, and Adjuvant Chemotherapy
A. Cancer Cell Characteristics
Cancer cells in stage III colon cancer are characterized by their ability to spread to regional lymph nodes while lacking distant metastases. In this patient's case, the cancer has involved two lymph nodes, which defines the stage III designation 1. Cancer cells demonstrate uncontrolled growth, invasion into surrounding tissues (T3 penetration through the bowel wall is common), and the capacity for lymphatic spread—all hallmarks of malignant transformation that distinguish them from normal colonic epithelium.
B. Most Commonly Reported Symptom
The most commonly reported symptom that led to this patient's diagnosis was severe anemia, which prompted the cascade of investigations. This anemia typically results from chronic occult bleeding from the tumor. In colon cancer patients, iron deficiency anemia is frequently the presenting complaint, particularly with right-sided lesions, though this patient had a partially obstructing tumor suggesting possible left-sided disease given the obstruction pattern.
C. Type of Chemotherapy Treatment
Since this patient has undergone complete tumor resection and is now receiving chemotherapy, she is receiving adjuvant chemotherapy 1. This is the standard of care for stage III colon cancer.
Adjuvant Chemotherapy Recommendations
For stage III colon cancer after curative resection, oxaliplatin-containing combination chemotherapy (such as FOLFOX) represents the standard treatment 1. The key considerations include:
Duration of Treatment
- Treatment duration should be 3-6 months depending on risk stratification 1
- For low-risk disease (T1-T3, N1): Either 3 or 6 months may be offered after shared decision-making
- For high-risk disease: 6 months is generally preferred
- Chemotherapy should ideally begin within 6 weeks after tumor resection 2, 3
Treatment Rationale
- Without adjuvant chemotherapy, recurrence rates after surgery alone can reach 50-80% 1
- Adjuvant chemotherapy significantly improves both disease-free survival and overall survival 1
- The liver is the most common site of recurrence, followed by peritoneum 4
Important Caveats
- Oxaliplatin carries risk of peripheral sensory neurotoxicity that increases with duration and cumulative dose 1
- This neurotoxicity may be severe and/or permanent
- A shared decision-making approach is essential, considering the patient's age (49 years), functional status, tumor characteristics (two lymph nodes involved), and tolerance for potential long-term neuropathy 1
Clinical Pitfall to Avoid
The timing of chemotherapy initiation is critical—patients who wait more than 5 weeks after surgery to start chemotherapy have significantly worse outcomes compared to those who start within 1-5 weeks 3. Ensure prompt referral to medical oncology and treatment initiation.
Given this patient's age and stage III disease with two positive nodes, she should receive the full benefit of oxaliplatin-based combination therapy, with duration (3 vs 6 months) determined through discussion of her risk profile and tolerance for neurotoxicity 1.